BEDFORD, Mass., & DES PLAINES, Ill.–(BUSINESS WIRE)–September 28, 2017–

Augmenix, Inc., a medical technology company that develops, manufactures and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy, together with Us TOO International, a nonprofit organization committed to improving the lives of those affected by prostate cancer, will hold a live webcast for prostate cancer patients and their caregivers on Monday, October 2, from 7:15 pm – 9:00 pm EST.

He will provide relevant clinical information on radiation therapy as a viable treatment for prostate cancer, and discuss the quality of life benefits associated with the utilization of SpaceOAR Hydrogel as an adjunctive therapy in protecting the rectum in men undergoing this form of treatment.

The session will also include an opportunity for webcast attendees to submit questions for Dr. Fried through an online chat.

“More than 160,000 men will be diagnosed with prostate cancer in 2017 and we’re on a mission to help educate those affected so they’re empowered to make informed decisions on all aspects of the disease,” said Chuck Strand, CEO, Us TOO International.

“We are privileged to partner with Us TOO on patient-centric activities that aim to educate, empower and support these men and their families.”

The text above is a summary, you can read full article here.